Global Lysosomal Storage Disease (LSD) Market (Fabry, Gaucher & Pompe): Industry Analysis & Outlook (2018-2022)

Increasing Preference Towards Gene Therapy Likely to Boost LSD Market

Lysosomal Storage Disease (LSD) is a genetic disorder that causes various types of nervous system disorders such as clinical abnormalities and cellular dysfunction. There are more than 65 categories of LSD. This disease can be classified into Lipid Metabolism Disorder and Glycoprotein Metabolism Disorder. Further Lipid Metabolism Disorder is categorized into Gaucher disease & Fabry disease and Glycoprotein Metabolism Disorder into Pompe disease. LSD develops mainly due to deficiency of lysosomal enzyme in the living body. A person suffering from LSD could experience problems like abnormal growth of bones, delay movement of body, deafness, blindness, dementia, respiratory problems, fatigue/weakness, bone & joint deformity, organ enlargement, lung dysfunction, severe & fatal physical & mental health deterioration.

The global LSD market is expected to grow with growing Ashkenazi (Eastern and Western Europe) population, increasing pharmaceutical R&D spending, growing disposable income, rising healthcare expenditure and accelerating economic growth. Key trends of this rare disease market includes progressing drugs under pipeline and increasing preference towards gene therapy. However, there are some factors which can hinder growth of the market including stringent regulations and limited access to patent rights.

The report “Global Lysosomal Storage Disease (LSD) Market (Fabry, Gaucher & Pompe): Industry Analysis & Outlook (2018-2022)”, provides an extensive research and detailed analysis of the present market along with future outlook.

The report discusses the major growth drivers, key tends & developments and challenges of the market, covering the global market. The report profiles the key players of the market including Pfizer Inc., Sanofi S.A., Shire Plc and Protalix BioTherapeutics, Inc.Please note: 10% free customization equates to up to 3 hours of analyst time.

1. Market Overview
1.1 Lysosomal Storage Disease (LSD)
1.2 Classification of LSD
1.3 Symptoms
1.4 Diagnosis
1.5 Treatment
1.6 Upcoming Treatment

2. Global LSD Market Analysis
2.1 Global LSD Market Forecast by Value
2.2 Global LSD Market Value by Category
2.3 Global Fabry Disease Market Forecast by Value
2.4 Global Fabry Disease Market Value by Drugs
2.4.1 Global Fabrazyme Sales Value
2.4.2 Global Replagal Sales Value
2.4.3 Global Galafold Sales Value
2.5 Global Gaucher Disease Market Forecast by Value
2.6 Global Gaucher Disease Market Value by Drugs
2.6.1 Global Cerezyme Sales Value
2.6.2 Global Vipriv Sales Value
2.6.3 Global Cerdelga Sales Value
2.7 Global Pompe Disease Market Forecast by Value
2.8 Global Pompe Disease Market Value by Drugs
2.8.1 Global Myozyme Sales Value

3. Market Dynamics
3.1 Growth Drivers
3.1.1 Growing Ashkenazi (Eastern and Western Europe) Population
3.1.2 Rising Pharmaceutical R&D Spending
3.1.3 Increasing Disposable Income
3.1.4 Growing Healthcare Expenditure
3.1.5 Accelerating Economic Growth
3.2 Key Trends & Developments
3.2.1 Progressing Drugs under Pipeline
3.2.2 Increasing Preference towards Gene Therapy
3.3 Challenges
3.3.1 Stringent Regulations
3.3.2 Limited Access to Patent Rights

4. Competitive Landscape
4.1 Global Market
4.1.1 Revenue Comparison of Key Players
4.1.2 Market Cap Comparison of Key Players
4.1.3 Global LSD Market-Annual Treatment Cost Comparison by Company

5. Company Profiles
5.1 Pfizer Inc.
5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
5.2 Sanofi S.A.
5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategies
5.3 Shire Plc
5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategies
5.4 Protalix BioTherapeutics, Inc.
5.4.1 Business Overview
5.4.2 Financial Overview
5.4.3 Business Strategies

List of Charts